Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Omalizumab in Chronic Idiopathic Urticaria

NCT02166151 is registered in ClinicalTrials.gov with Rabin Medical Center as lead sponsor.

NCT NCT02166151
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02166151 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Omalizumab in Chronic Idiopathic Urticaria
Lead sponsor
Rabin Medical Center
Phase
Phase 3
Overall status
Unknown status
Start date
July 31, 2014
Completion date
June 30, 2016
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic idiopathic urticaria